US EditionEnd-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle Leader
“What’s in a name? That which we call a rose by any other name would smell as sweet,” Juliet famously observed in Shakespeare’s Romeo and Juliet. More than 400 years later, Fujifilm’s Life Sciences Group is renaming two of its companies, in a rebranding intended to position parent company Fujifilm as a strategic partner to drug and vaccine developers across the development life cycle. Lars Petersen, Fujifilm Biotechnologies president and CEO Fuj…
1 Articles
1 Articles
All
Left
Center
Right
End-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle Leader
“What’s in a name? That which we call a rose by any other name would smell as sweet,” Juliet famously observed in Shakespeare’s Romeo and Juliet. More than 400 years later, Fujifilm’s Life Sciences Group is renaming two of its companies, in a rebranding intended to position parent company Fujifilm as a strategic partner to drug and vaccine developers across the development life cycle. Lars Petersen, Fujifilm Biotechnologies president and CEO Fuj…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
